Making the fight to contain the dreaded Coronavirus difficult, new variants of the virus were detected in a few countries. The new variants come with more transmissibility raising a question of whether the vaccines can take on the new variants or not.
Top Research Institute in the United States, the National Institute of Health (NIH) had conducted a study on India's indigenous COVID-19 vaccine Covaxin developed by Hyderabad-based Bharat Biotech in collaboration with the medical research body Indian Council of Medical Research(ICMR).
During the study, the research body had found out that Covaxin neutralises the Alpha and Delta variants of the novel Coronavirus effectively.
The researchers have examined the blood serum samples of people administered with the Covaxin doses and found out that those who received the vaccine will result in developing antibodies that neutralises the two variants of the pandemic.
Saying that the phase 2 clinical trials of the vaccine proves that the vaccine is safe and neutralises the two variants, the research body said, the vaccine dose stimulates the immune system, which in turn results in developing antibodies.
The NIH added that, the Covaxin offers cent percent efficacy against the severe Covid virus, while it has an efficacy of 78 percent and 70 percent against the symptomatic virus and asymptomatic virus respectively.
Top Research Institute in the United States, the National Institute of Health (NIH) had conducted a study on India's indigenous COVID-19 vaccine Covaxin developed by Hyderabad-based Bharat Biotech in collaboration with the medical research body Indian Council of Medical Research(ICMR).
During the study, the research body had found out that Covaxin neutralises the Alpha and Delta variants of the novel Coronavirus effectively.
The researchers have examined the blood serum samples of people administered with the Covaxin doses and found out that those who received the vaccine will result in developing antibodies that neutralises the two variants of the pandemic.
Saying that the phase 2 clinical trials of the vaccine proves that the vaccine is safe and neutralises the two variants, the research body said, the vaccine dose stimulates the immune system, which in turn results in developing antibodies.
The NIH added that, the Covaxin offers cent percent efficacy against the severe Covid virus, while it has an efficacy of 78 percent and 70 percent against the symptomatic virus and asymptomatic virus respectively.